珠海都市网
您当前的位置 :首页 > 文传商讯 > 正文
Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older
2026年10月12日 18:26:33来源:作者:
【摘要】 New Nemluvio (nemolizumab) post-hoc data from the ARCADIA long-term extension (LTE) study showed the majority of Week 16 responders maintained deep and lasting skin lesion and itch response for up to three years1Additional long-term data fu

New Nemluvio (nemolizumab) post-hoc data from the ARCADIA long-term extension (LTE) study showed the majority of Week 16 responders maintained deep and lasting skin lesion and itch response for up to three years1
Additional long-term data further demonstrate Nemluvio’s consistent safety profile and sustained efficacy, including improvements in skin clearance, itch, sleep and quality of life in adults with prurigo nodularis up to 148 weeks, and people with atopic dermatitis aged 12 and older up to 152 weeks2,3
Phase II pediatric data will also be presented, with nemolizumab driving meaningful and sustained improvements in children aged 2-11 years with moderate-to-severe atopic dermatitis4
Alongside a product theatre exploring how targeted IL-31 treatment may impact patient outcomes, these findings reinforce Galderma's leadership in advancing treatment goals in atopic dermatitis and prurigo nodularis

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new data regarding the use of Nemluvio for atopic dermatitis and prurigo nodularis to be presented at the 2026 Fall Clinical Dermatology Conference, taking place from October 08-11 in Las Vegas, United States. This includes a new post-hoc analysis from the ARCADIA LTE study showing that in adults and adolescents aged 12 and older who achieved an early response at Week 16 in the ARCADIA trial, Nemluvio achieved deep and lasting skin lesion and itch responses for up to three years.1 The data add to the growing evidence supporting the long-term efficacy of Nemluvio, underscoring Galderma's commitment to advancing the science for people living with moderate-to-severe atopic dermatitis and prurigo nodularis.

 

“Patients and physicians increasingly expect more from treatment than temporary symptom relief. The data presented at Fall Clinical reinforce our confidence in Nemluvio's potential to deliver durable disease control, with evidence spanning deep and sustained responses on skin and itch through three years in adults and adolescents, and a consistent long-term safety and efficacy profile. Together, these findings reflect Galderma's continued focus on redefining what is possible for people living with atopic dermatitis and prurigo nodularis.”

 

BILL ANDRIOPOULOS, PH.D.

HEAD OF GLOBAL MEDICAL AFFAIRS

GALDERMA

 

 

责任编辑: admin

看新闻,关注新闻

百度网友:念旧 cunese
评论:我伸出三根手指说:“送你五个字,一派胡言!“

本网网友:看破红尘之罪
评论:有一天,全世界都不要你了。不要慌,来找我,我会告诉你,我也不要你。

其它网友:念旧-  Tender
评论:职场三定律;:要么忍!要么狠!要么滚!

腾讯网友:冷忆ゆ Conquer
评论:警察说:"你不知道开车不让打电话吗?"我一脸疑惑的说:"我没打电话呀?.....我发短信来着!"

天涯网友:离岛║Bombastic Love
评论:> 有人争取,就会有人失去

猫扑网友:眼泪那么无辜
评论:过着八戒的生活,却想要悟空的身材。

搜狐网友:冷笑你的无知
评论:令我感到骄傲和自豪的是,至今为止,地球仍被我踩在脚下。

凤凰网友:想哭卻無淚
评论:如果有人和你说:不要脸。你可以对他说:对你根本不需要有脸!

淘宝网友:别走停下来
评论:哥,不寂寞。因为有寂寞陪着哥。

网易网友:曲终人离场
评论:这么不要脸,这么没心没肺,你的体重应该会很轻吧

相关阅读
分享到:
版权和免责申明

珠海都市网所有文字、图片、视频、音频等资料均来自互联网,不代表本站赞同其观点,本站亦不为其版权负责。相关作品的原创性、文中陈述文字以及内容数据庞杂本站无法一一核实,如果您发现本网站上有侵犯您的合法权益的内容,请联系我们,本网站将立即予以删除!